NY-CARESTREAM-HEALTH
20.2.2024 21:42:30 CET | Business Wire | Press release
Carestream Health will exhibit its expanding portfolio of innovative, industry-leading medical imaging solutions at the annual European Congress of Radiology (ECR) from 28th February to 3rd March in Vienna Building on its century-long foundation of imaging research science, the company will showcase its diagnostic imaging solutions that help improve clinical outcomes, enhance the imaging experience for users and patients, and strengthen the financial position of healthcare facilities.
“We understand that the radiology industry across the world is facing challenges such as a shortage of skilled staff and consequently radiologists are dealing with increased workload demands,” said Jane Moverley, International Sales Director, Digital Radiology. “This is why Carestream solutions add significant value to the imaging process. For example, our new DRX-LC Detector helps deliver high-quality, long-length imaging with a single exposure to deliver a more user-friendly workflow, optimize productivity, and ease the physical stress on radiographers. We are also showcasing our expanding line of X-ray solutions that deliver high-quality imaging to meet our customers’ needs at an affordable price.”
Solutions to Help Improve Clinical Outcomes
DRX-Compass X-ray System
- Exceptional image quality
- Scalable and upgradeable technology
- Available in floor-mount or OTC configuration
DRX-Revolution Mobile X-ray System
- Our original X-ray Room on Wheels offering provides superb image quality, maneuverability, and on-board storage.
- Robust functionality with Carestream’s most advanced image processing is available in a single platform.
- Low-profile design and flexibility mean you can easily capture images wherever you need them most.
Solutions to Enhance User and Patient Experience
DRX-LC Detector
- Captures long-length images with a single exposure
- Saves exam time and speeds up workflow
- Decreases retakes
- Allows a higher level of patient comfort
ImageView Software
- Provides high-image quality with AI and advanced image processing technology
- Delivers a quick and sleek operator experience via a single-screen workflow
- Allows users to track analytics on key parameters such as exposure rates and number of rejections
- Provides dose reporting
Solutions to Strengthen Financial Position
New DRX-Rise Mobile X-ray System
- Cutting-edge features in a fully-integrated, digital X-ray unit provide an affordable path to digital imaging.
- Efficiency-boosting features include two touchscreen displays, a state-of-the-art lithium battery, and in-bin detector charging.
- Bedside imaging minimizes disruption and helps deliver an improved patient experience.
DR Detectors
- These are the right detector for every facility, workflow, and budget.
- X-Factor capability lets you share detectors across your facility.
- Upgrade your existing film or CR systems to full wireless DR with a retrofit system and detector.
- Various cassette sizes let you choose the best fit.
Full Suite of Imaging Solutions on Display at ECR 2024
Carestream will also display additional imaging innovations at Expo X2-Booth 220 at ECR. These will include the DRX-Compass X-ray System, DRX-Rise Mobile X-ray System, and DRX-Revolution Mobile X-ray System, as well as our suite of DR Detectors.
Schedule an appointment to discuss Carestream’s latest innovations and other medical imaging solutions at ECR 2024.
About Carestream Health
Carestream is a worldwide provider of medical imaging systems; X-ray imaging systems for non-destructive testing; and precision contract coating services for a wide range of industrial, medical, electronic, and other applications—all backed by a global service and support network. For more information about the company’s broad portfolio of products, solutions, and services, please contact your Carestream representative, or call 1-888-777-2072, or visit www.carestream.com.
CARESTREAM is a trademark of Carestream Health.
“Rx only”
2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220770604/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom